COPENHAGEN, Denmark, July 1, 2014 (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) announces the appointment of Helle Skov (54 years) as new Executive Vice President (Product Supply) and member of the Board of Management of ALK-Abelló A/S.
Helle Skov will be responsible for ALK's Product Supply with production sites in Denmark, Spain, France, the Netherlands and the USA.
Helle Skov holds a Master of Science in Pharmacy and a PhD, both from the University of Copenhagen. She joins ALK from a position as Vice President and Head of Global Supply Chain, Takeda. From her positions at Takeda, Nycomed and Novo Nordisk she has gained significant experience in managing international pharmaceutical production.
Helle Skov will start at ALK no later than 1 October 2014.
For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy – a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck and Torii to commercialise sublingual allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.